2020
Chapter Four Clinical overview of NMDA-R antagonists and clinical practice
Davoudian PA, Wilkinson ST. Chapter Four Clinical overview of NMDA-R antagonists and clinical practice. Advances In Pharmacology 2020, 89: 103-129. PMID: 32616204, DOI: 10.1016/bs.apha.2020.04.004.ChaptersConceptsNMDA receptor antagonistReceptor antagonistGlutamatergic systemClinical trialsPathophysiology of depressionLevels of monoaminesNMDA-R antagonistsTreatment of depressionRole of glutamatePatient's therapeutic responseRecent FDA approvalIntranasal esketamineMonoamine hypothesisPathophysiological mechanismsClinical overviewTherapeutic responseCurrent treatmentClinical practiceTranslational studiesMental illnessFDA approvalNeural circuitsAntagonistDepressionPotential mechanisms
2013
Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry 2013, 18: 1199-1204. PMID: 23337947, PMCID: PMC3646075, DOI: 10.1038/mp.2012.194.Peer-Reviewed Original ResearchConceptsFunctional connectivityNegative symptomsGamma-aminobutyric acid (GABA) neuronsNMDA receptor antagonist ketamineAspartate glutamate receptor antagonistContinuous ketamine infusionGlutamate receptor antagonistsNMDA-R antagonistsCortical functional connectivityNMDA-R antagonist ketamineSchizophrenia-like symptomsHealthy human subjectsNegative Syndrome ScaleBrain functional connectivityPrimary samplesRegion-specific mannerFunctional magnetic resonanceKetamine infusionReceptor antagonistPathological increaseSyndrome ScaleSymptomsPreclinical researchKetamineBrain oscillations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply